{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:50:50Z","timestamp":1789213850783,"version":"build-2803163510"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Cluster of Excellence \u2018Precision Medicine in Chronic Inflammation\u2019"},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024172","name":"Schleswig-Holstein","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024172","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psoriasis is associated with a significant comorbidity burden, especially cardiovascular and metabolic complications. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, used to treat obesity and diabetes, could potentially reduce comorbidities in patients with psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate all-cause mortality, cardiovascular, inflammatory and psychiatric outcomes, and adverse events in patients with psoriasis treated with GLP-1RAs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective population-based cohort study used real-world data from the US TriNetX database. Patients with psoriasis who were treated for diabetes or obesity with a GLP-1RA during the follow-up period of 2\u2005years were compared with those treated with other systemic antidiabetic or antiobesity drugs. After 1 : 1 propensity score matching for relevant risk factors, 3048 participants were included in each cohort. Primary outcomes included the risk of cardiometabolic, psychiatric and autoimmune sequelae of psoriasis, as well as all-cause mortality and potential adverse drug events. The analysis was repeated using cohorts without psoriasis and the results were further validated through two sensitivity analyses involving (i) later follow-up periods or (ii) the exclusion of patients with pustular psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the matched cohorts of 3048 patients with psoriasis treated with a GLP-1RA [60.4% women, mean (SD) age 56.94 (12.02) years] vs. other antidiabetic and antiobesity drugs [61.9% women, mean (SD) age 56.42 (14.16) years], GLP-1RA treatment was associated with significantly decreased all-cause mortality [hazard ratio (HR) 0.219, 95% confidence interval (CI) 0.123\u20130.391; P &amp;lt; 0.001] and reduced risk of major adverse cardiac events (HR 0.561, 95% CI 0.442\u20130.714; P &amp;lt; 0.001). Additionally, lower risks for alcohol (HR 0.346, 95% CI 0.174\u20130.685; P = 0.009) and substance abuse (HR 0.510, 95% CI 0.350\u20130.743; P = 0.002) were found. Typical adverse drug events were not more frequent in the GLP-1RA cohort. The risk reductions were more pronounced in the cohorts with psoriasis than in those with obesity or diabetes without psoriasis. The findings were consistent across all sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GLP-1RA treatment was safe and associated with reduced risks of cardiovascular and psychiatric comorbidities, as well as lower mortality in patients with psoriasis, with risk reductions markedly higher than in cohorts without psoriasis. Physicians should consider this drug class for patients with psoriasis and comorbid obesity or diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf346","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T11:55:26Z","timestamp":1756554926000},"page":"59-66","source":"Crossref","is-referenced-by-count":22,"title":["Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: a large-scale cohort study"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-7148","authenticated-orcid":false,"given":"Henning","family":"Olbrich","sequence":"first","affiliation":[{"name":"Department of Dermatology, Allergy, and Venerology, University of L\u00fcbeck , L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9971-9151","authenticated-orcid":false,"given":"Khalaf","family":"Kridin","sequence":"additional","affiliation":[{"name":"Unit of Dermatology and Skin Research Laboratory, Galilee Medical Center , Nahariya ,","place":["Israel"]},{"name":"Azrieli Faculty of Medicine, Bar-Ilan University , Safed ,","place":["Israel"]},{"name":"L\u00fcbeck Institute of Experimental Dermatology, University of L\u00fcbeck , L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0053-4312","authenticated-orcid":false,"given":"Henner","family":"Zirpel","sequence":"additional","affiliation":[{"name":"Comprehensive Center for Inflammation Medicine, University-Hospital Schleswig-Holstein , L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Hernandez","sequence":"additional","affiliation":[{"name":"TriNetX, LLC , Cambridge, MA ,","place":["USA"]},{"name":"Biomedical Informatics Group Artificial Intelligence Department, E.T.S.I. Inform\u00e1ticos, Universidad Polit\u00e9cnica de Madrid , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6701-048X","authenticated-orcid":false,"given":"Christian D","family":"Sadik","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Allergy, and Venerology, University of L\u00fcbeck , L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-9841","authenticated-orcid":false,"given":"Evelyn","family":"Gaffal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Allergy, and Venerology, University of L\u00fcbeck , L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-550X","authenticated-orcid":false,"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"Comprehensive Center for Inflammation Medicine, University-Hospital Schleswig-Holstein , L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1394-1737","authenticated-orcid":false,"given":"Ralf J","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Allergy, and Venerology, University of L\u00fcbeck , L\u00fcbeck ,","place":["Germany"]},{"name":"L\u00fcbeck Institute of Experimental Dermatology, University of L\u00fcbeck , L\u00fcbeck ,","place":["Germany"]},{"name":"Comprehensive Center for Inflammation Medicine, University-Hospital Schleswig-Holstein , L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"2026010607270068300_ljaf346-B1","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"2026010607270068300_ljaf346-B2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2133.2006.07562.x","article-title":"Psoriasis: a possible risk factor for development of coronary artery calcification","volume":"156","author":"Ludwig","year":"2007","journal-title":"Br J Dermatol"},{"key":"2026010607270068300_ljaf346-B3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026010607270068300_ljaf346-B4","doi-asserted-by":"crossref","first-page":"918224","DOI":"10.3389\/fimmu.2022.918224","article-title":"The association between psoriasis and risk of cardiovascular disease: a Mendelian randomization analysis","volume":"13","author":"Gao","year":"2022","journal-title":"Front Immunol"},{"key":"2026010607270068300_ljaf346-B5","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/ced.12013","article-title":"Alcohol and psoriasis: sobering thoughts","volume":"38","author":"Adamzik","year":"2013","journal-title":"Clin Exp Dermatol"},{"key":"2026010607270068300_ljaf346-B6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"2026010607270068300_ljaf346-B7","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"2026010607270068300_ljaf346-B8","doi-asserted-by":"crossref","first-page":"105123","DOI":"10.1016\/j.ebiom.2024.105123","article-title":"Increased cardiovascular risks and mortality in prurigo nodularis: a global cohort study","volume":"103","author":"Olbrich","year":"2024","journal-title":"EBioMedicine"},{"key":"2026010607270068300_ljaf346-B9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jaad.2022.10.031","article-title":"Isotretinoin and the risk of psychiatric disturbances: a global study shedding new light on a debatable story","volume":"88","author":"Kridin","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026010607270068300_ljaf346-B10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jacc.2016.10.060","article-title":"Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies","volume":"69","author":"Elze","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026010607270068300_ljaf346-B11","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/jdv.18044","article-title":"Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis","volume":"36","author":"Wu","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026010607270068300_ljaf346-B12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ijo.2008.216","article-title":"Increased activity of interleukin-23\/interleukin-17 proinflammatory axis in obese women","volume":"33","author":"Sumarac-Dumanovic","year":"2009","journal-title":"Int J Obes (Lond)"},{"key":"2026010607270068300_ljaf346-B13","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1365-2133.2008.08742.x","article-title":"Serum leptin levels, skin leptin and leptin receptor expression in psoriasis","volume":"159","author":"Cerman","year":"2008","journal-title":"Br J Dermatol"},{"key":"2026010607270068300_ljaf346-B14","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.ijo.0801623","article-title":"Plasma leptin is independently associated with the intima-media thickness of the common carotid artery","volume":"25","author":"Ciccone","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2026010607270068300_ljaf346-B15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2020.07.008","article-title":"Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design","volume":"229","author":"Ryan","year":"2020","journal-title":"Am Heart J"},{"key":"2026010607270068300_ljaf346-B16","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026010607270068300_ljaf346-B17","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1089\/met.2024.0115","article-title":"Changes in transient elastography with glucagon-like peptide-1 receptor agonist use in metabolic dysfunction-associated steatotic liver disease: a real-world retrospective analysis","volume":"22","author":"Akhverdyan","year":"2024","journal-title":"Metab Syndr Relat Disord"},{"key":"2026010607270068300_ljaf346-B18","first-page":"11","article-title":"The impact of glucagon-like peptide 1 receptor agonists on obstructive sleep apnoea: a scoping review","volume":"12","author":"Le","year":"2024","journal-title":"Pharmacy (Basel)"},{"key":"2026010607270068300_ljaf346-B19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaad.2017.05.019","article-title":"Psoriasis and suicidality: a systematic review and meta-analysis","volume":"77","author":"Singh","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026010607270068300_ljaf346-B20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3390\/ijms23020669","article-title":"The brain\u2013skin axis in psoriasis \u2013 psychological, psychiatric, hormonal, and dermatological aspects","volume":"23","author":"Marek-Jozefowicz","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026010607270068300_ljaf346-B21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4088\/JCP.23m15068","article-title":"Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: a case series","volume":"85","author":"Richards","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"2026010607270068300_ljaf346-B22","doi-asserted-by":"crossref","first-page":"e159863","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"2026010607270068300_ljaf346-B23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","article-title":"Exploration of the potential association between GLP-1 receptor agonists and suicidal or \u00adself-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database","volume":"22","author":"Zhou","year":"2024","journal-title":"BMC Med"},{"key":"2026010607270068300_ljaf346-B24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.euroneuro.2024.02.003","article-title":"Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: insights from pharmacovigilance measures and unmasking analysis","volume":"82","author":"Guirguis","year":"2024","journal-title":"Eur Neuropsychopharmacol"},{"key":"2026010607270068300_ljaf346-B25","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1210\/en.2011-1443","article-title":"GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake","volume":"153","author":"Alhadeff","year":"2012","journal-title":"Endocrinology"},{"key":"2026010607270068300_ljaf346-B26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.physbeh.2013.04.003","article-title":"Role of central glucagon-like peptide-1 in stress regulation","volume":"122","author":"Ghosal","year":"2013","journal-title":"Physiol Behav"},{"key":"2026010607270068300_ljaf346-B27","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial","volume":"33","author":"Lin","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2026010607270068300_ljaf346-B28","first-page":"23","article-title":"Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes","volume":"2023","author":"Malavazos","year":"2023","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2026010607270068300_ljaf346-B29","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/09546634.2021.1882658","article-title":"Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies","volume":"33","author":"Chang","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2026010607270068300_ljaf346-B30","first-page":"143","article-title":"Impact of GLP-1 receptor agonists on psoriasis and cardiovascular comorbidities: a narrative review","volume":"14","author":"Haran","year":"2024","journal-title":"Psoriasis (Auckl)"},{"key":"2026010607270068300_ljaf346-B31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.medcli.2023.05.021","article-title":"Effects of liraglutide among patients living with psoriasis and obesity","volume":"161","author":"Nicolau","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"2026010607270068300_ljaf346-B32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/RHU.0000000000001949","article-title":"Glucagon-like peptide 1 receptor agonists in patients with inflammatory arthritis or psoriasis: a scoping review","volume":"30","author":"Karacabeyli","year":"2024","journal-title":"J Clin Rheumatol"},{"key":"2026010607270068300_ljaf346-B33","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/ajcn\/nqaa328","article-title":"Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial","volume":"113","author":"Gudbergsen","year":"2021","journal-title":"Am J Clin Nutr"},{"key":"2026010607270068300_ljaf346-B34","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1007\/s00125-011-2232-3","article-title":"Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis","volume":"54","author":"Hogan","year":"2011","journal-title":"Diabetologia"},{"key":"2026010607270068300_ljaf346-B35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/bjd.12886","article-title":"Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: a prospective case-series study","volume":"171","author":"Buysschaert","year":"2014","journal-title":"Br J Dermatol"},{"key":"2026010607270068300_ljaf346-B36","doi-asserted-by":"crossref","first-page":"997578","DOI":"10.3389\/fimmu.2022.997578","article-title":"GLP-1 receptor agonist as a modulator of innate immunity","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"2026010607270068300_ljaf346-B37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.yexmp.2019.01.014","article-title":"GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK","volume":"107","author":"Yang","year":"2019","journal-title":"Exp Mol Pathol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf346\/64195746\/ljaf346.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/1\/59\/64195746\/ljaf346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/1\/59\/64195746\/ljaf346.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:27:15Z","timestamp":1767702435000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/194\/1\/59\/8246223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,9,3]]},"published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf346","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,9,3]]}}}